Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27822327 | 0.97 | LMNA (0.46) | LMNATRPV1TRPA1BLMMEN1 | |
| SCHEMBL4931822 | 0.97 | LMNA (0.46) | LMNATRPV1TRPA1BLMMEN1 | |
| SCHEMBL15873598 | 0.97 | LMNA (0.46) | LMNATRPV1TRPA1BLMMEN1 | |
| SCHEMBL4930442 | 0.97 | LMNA (0.46) | LMNATRPV1TRPA1BLMMEN1 | |
| SCHEMBL27841585 | 0.97 | LMNA (0.46) | LMNATRPV1TRPA1BLMMEN1 | |
| SCHEMBL1258066 | 0.97 | LMNA (0.46) | LMNATRPV1TRPA1BLMMEN1 | |
| SCHEMBL15873627 | 0.97 | LMNA (0.46) | LMNATRPV1TRPA1BLMMEN1 | |
| SCHEMBL4926969 | 0.97 | LMNA (0.46) | LMNATRPV1TRPA1BLMMEN1 | |
| SCHEMBL21774118 | 0.97 | LMNA (0.46) | LMNATRPV1TRPA1BLMMEN1 | |
| SCHEMBL11711042 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014108526-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF PIPECOLIDEPSIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2014-07-17 | — | — | WO | disclosed |
| EP-1120407-B1 | Cystine derivatives | AJINOMOTO KK (JP) | 2013-02-20 | — | — | EP | disclosed |
| US-20080119551-A1 | SKIN COSMETICS COMPRISING A CYSTINE DERIVATIVE AND A CHEMICAL PEELING AGENT, A BACTERICIDE, AN ANIONIC SUFACTANT, OR A CATIONIC SURFACTANT | AJINOMOTO CO. INC (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7375085-B1 | Melanocyte-stimulating hormone inhibitors | AJINOMOTO CO., INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7105570-B2 | Cysteine derivatives | AJINOMOTO CO., INC. (JP) | 2006-09-12 | — | — | US | disclosed |
| US-20040156802-A1 | Cosmetics or external preparations for skin | AJINOMOTO CO., INC. (JP) | 2004-08-12 | — | — | US | disclosed |
| US-6703031-B1 | OXIDATIVE STRESS INHIBITOR; RETARDING AGING OF SKIN | AJINOMOTO CO., INC. (JP) | 2004-03-09 | — | — | US | disclosed |
| EP-1374831-A1 | COMSETICS OR EXTERNAL PREPARAIOTNS FOR SKIN | Ajinomoto Co., Inc. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-20030194417-A1 | Cysteine derivatives | AJINOMOTO CO. INC (JP) | 2003-10-16 | — | — | US | disclosed |
| US-6602492-B2 | Cysteine derivatives | AJINOMOTO CO., INC. (JP) | 2003-08-05 | — | — | US | disclosed |
| US-20020115723-A1 | Cysteine derivatives | AJINOMOTO CO., INC. (JP) | 2002-08-22 | — | — | US | disclosed |
| EP-1174437-A1 | MELANOCYTE-STIMULATING HORMONE INHIBITORS | Ajinomoto Co., Inc. (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1120407-A1 | CYSTEINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2001-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040156802-A1 | Cosmetics or external preparations for skin | CUTA, PSAP, CTH | LMNA 2614/4885TRPV1 49/4885TRPA1 38/4885 |
| US-20020115723-A1 | Cysteine derivatives | NFE2L2, GCLC, KEAP1 | LMNA 4321/4885TRPV1 1439/4885TRPA1 370/4885 |
| US-20030194417-A1 | Cysteine derivatives | NFE2L2, GCLC, KEAP1 | LMNA 4321/4885TRPV1 1439/4885TRPA1 370/4885 |
| US-20080119551-A1 | SKIN COSMETICS COMPRISING A CYSTINE DERIVATIVE AND A CHEMICAL PEELING AGENT, A BACTERICIDE, AN ANIONIC SUFACTANT, OR A CATIONIC SURFACTANT | CUTA, CTH, SRM | LMNA 3363/4885TRPV1 211/4885TRPA1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.